Skip to main content
Erschienen in: Wiener klinische Wochenschrift 3-4/2015

01.02.2015 | original article

Ki-67 proliferation index in patients with placenta previa percreta in the third trimester

verfasst von: Assist. Prof. Dr. Nese Hilali, Sezen Kocarslan, Mehmet Vural, Adnan Incebiyik, Aysun Camuzcuoglu, Hakan Camuzcuoglu

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 3-4/2015

Einloggen, um Zugang zu erhalten

Abstract

Aim

The purpose of this study was to investigate proliferative capacity of placenta previa percreta in the third trimester via evaluating Ki-67 proliferating index.

Methods

The paraffin blocks of placental tissues, which were obtained from the patients who underwent hysterectomy for placenta previa percreta (n = 12, gestational age > 28 weeks), from legal abortions (n = 12, gestational age < 10 weeks), and of cesarean deliveries with the indication of previous cesarean section, without any complication (n = 12, gestational age > 38 weeks), between January 2011 and April 2013, were included into the study. The paraffin blocks of the patients were stained with Ki-67 (proliferating cell marker) immunohistochemically, and Ki-67 proliferation index levels were calculated.

Results

Ki-67 proliferation index levels were higher in patients with legal abortions than patients with placenta percreta or noncomplicated cesarean delivery group. However, any statistically significant difference was not detected between the percreta and noncomplicated groups (p > 0.05).

Conclusion

The tissue samples of the patients with placenta previa percreta exhibited low proliferative capacity similar to the samples of normal placentation group.
Literatur
1.
Zurück zum Zitat Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol. 2005;192(5):1458–61.CrossRefPubMed Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol. 2005;192(5):1458–61.CrossRefPubMed
2.
Zurück zum Zitat Zepiridis L, Zafrakas M, Theodoridis TD, et al. Human placental lactogen and color doppler in predicting expulsion of retained adherent placenta: a new clinical observation. Arch Gynecol Obstet. 2009;280(6):1041–4. doi:10.1007/s00404-009-1045-9.CrossRefPubMed Zepiridis L, Zafrakas M, Theodoridis TD, et al. Human placental lactogen and color doppler in predicting expulsion of retained adherent placenta: a new clinical observation. Arch Gynecol Obstet. 2009;280(6):1041–4. doi:10.1007/s00404-009-1045-9.CrossRefPubMed
3.
Zurück zum Zitat Clément D, Kayem G, Cabrol D. Conservative treatment of placenta percreta: a safe alternative. Eur J Obstet Gynecol Reprod Biol. 2004;114(1):108–9.CrossRefPubMed Clément D, Kayem G, Cabrol D. Conservative treatment of placenta percreta: a safe alternative. Eur J Obstet Gynecol Reprod Biol. 2004;114(1):108–9.CrossRefPubMed
4.
Zurück zum Zitat Ferretti C, Bruni L, Dangles-Marie V, et al. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 2006;13(2):121–41.CrossRefPubMed Ferretti C, Bruni L, Dangles-Marie V, et al. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 2006;13(2):121–41.CrossRefPubMed
5.
Zurück zum Zitat Khan M, Sachdeva P, Arora R, et al. Conservative management of morbidly adherant placenta—a case report and review of literature. Placenta. 2013;34(10):963–6. doi:10.1016/j.placenta.2013.04.016.CrossRefPubMed Khan M, Sachdeva P, Arora R, et al. Conservative management of morbidly adherant placenta—a case report and review of literature. Placenta. 2013;34(10):963–6. doi:10.1016/j.placenta.2013.04.016.CrossRefPubMed
6.
Zurück zum Zitat Steins Bisschop CN, Schaap TP, Vogelvang TE, et al. Invasive placentation and uterus preserving treatment modalities: a systematic review. Arch Gynecol Obstet. 2011;284(2):491–502. doi:10.1007/s00404-011-1934-6.CrossRefPubMedCentralPubMed Steins Bisschop CN, Schaap TP, Vogelvang TE, et al. Invasive placentation and uterus preserving treatment modalities: a systematic review. Arch Gynecol Obstet. 2011;284(2):491–502. doi:10.1007/s00404-011-1934-6.CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Barber JT Jr., Tressler TB, Willis GS, et al. Arteriovenous malformation identification after conservative management of placenta percreta with uterine artery embolization and adjunctive therapy. Am J Obstet Gynecol. 2011;204(5):e4–8. doi:10.1016/j.ajog.2011.01.001.CrossRefPubMed Barber JT Jr., Tressler TB, Willis GS, et al. Arteriovenous malformation identification after conservative management of placenta percreta with uterine artery embolization and adjunctive therapy. Am J Obstet Gynecol. 2011;204(5):e4–8. doi:10.1016/j.ajog.2011.01.001.CrossRefPubMed
8.
Zurück zum Zitat Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMed Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMed
9.
Zurück zum Zitat Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta. 2008;29(7):639–45. doi:10.1016/j.placenta.2008.04.008.CrossRefPubMed Tantbirojn P, Crum CP, Parast MM. Pathophysiology of placenta creta: the role of decidua and extravillous trophoblast. Placenta. 2008;29(7):639–45. doi:10.1016/j.placenta.2008.04.008.CrossRefPubMed
10.
Zurück zum Zitat Tseng JJ, Hsu SL, Ho ES, et al. Differential expression of angiopoietin-1, angiopoietin-2, and Tie receptors in placentas from pregnancies complicated by placenta accreta. Am J Obstet Gynecol. 2006;194(2):564–71.CrossRefPubMed Tseng JJ, Hsu SL, Ho ES, et al. Differential expression of angiopoietin-1, angiopoietin-2, and Tie receptors in placentas from pregnancies complicated by placenta accreta. Am J Obstet Gynecol. 2006;194(2):564–71.CrossRefPubMed
11.
Zurück zum Zitat Wehrum MJ, Buhimschi IA, Salafia C, et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. Am J Obstet Gynecol. 2011;204(5):411.e1–11. doi:10.1016/j.ajog.2010.12.027.CrossRefPubMedCentralPubMed Wehrum MJ, Buhimschi IA, Salafia C, et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. Am J Obstet Gynecol. 2011;204(5):411.e1–11. doi:10.1016/j.ajog.2010.12.027.CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Kim KR, Jun SY, Kim JY, et al. Implantation site intermediate trophoblasts in placenta cretas. Mod Pathol. 2004;17:1483–90.CrossRefPubMed Kim KR, Jun SY, Kim JY, et al. Implantation site intermediate trophoblasts in placenta cretas. Mod Pathol. 2004;17:1483–90.CrossRefPubMed
13.
Zurück zum Zitat Stanek J, Drummond Z. Occult placenta accreta: the missing link in the diagnosis of abnormal placentation. Pediatr Dev Pathol. 2007;10:266–73.CrossRefPubMed Stanek J, Drummond Z. Occult placenta accreta: the missing link in the diagnosis of abnormal placentation. Pediatr Dev Pathol. 2007;10:266–73.CrossRefPubMed
15.
Zurück zum Zitat Skubisz MM, Tong S. The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review. ISRN Obstet Gynecol. 2012;2012:637094. doi:10.5402/2012/637094.CrossRefPubMedCentralPubMed Skubisz MM, Tong S. The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review. ISRN Obstet Gynecol. 2012;2012:637094. doi:10.5402/2012/637094.CrossRefPubMedCentralPubMed
16.
Zurück zum Zitat Samra ZQ, Ahmad S, Javeid M, et al. Anticancer medicines (doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron. Prep Biochem Biotechnol. 2013;43(8):781–97. doi:10.1080/10826068.2013.782042.CrossRefPubMed Samra ZQ, Ahmad S, Javeid M, et al. Anticancer medicines (doxorubicin and methotrexate) conjugated with magnetic nanoparticles for targeting drug delivery through iron. Prep Biochem Biotechnol. 2013;43(8):781–97. doi:10.1080/10826068.2013.782042.CrossRefPubMed
17.
Zurück zum Zitat Stitely ML, Gerard Jackson M, Holls WH. Log-linear human chorionic gonadotropin elimination in cases of retained placenta percreta. Arch Gynecol Obstet. 2013. doi:10.1007/s00404-013-2950-5. Stitely ML, Gerard Jackson M, Holls WH. Log-linear human chorionic gonadotropin elimination in cases of retained placenta percreta. Arch Gynecol Obstet. 2013. doi:10.1007/s00404-013-2950-5.
18.
Zurück zum Zitat Sentilhes L, Ambroselli C, Kayem G, et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol. 2010;115(3):526–34.CrossRefPubMed Sentilhes L, Ambroselli C, Kayem G, et al. Maternal outcome after conservative treatment of placenta accreta. Obstet Gynecol. 2010;115(3):526–34.CrossRefPubMed
Metadaten
Titel
Ki-67 proliferation index in patients with placenta previa percreta in the third trimester
verfasst von
Assist. Prof. Dr. Nese Hilali
Sezen Kocarslan
Mehmet Vural
Adnan Incebiyik
Aysun Camuzcuoglu
Hakan Camuzcuoglu
Publikationsdatum
01.02.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 3-4/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0634-1

Weitere Artikel der Ausgabe 3-4/2015

Wiener klinische Wochenschrift 3-4/2015 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Mitteilungen der gesellschaft der ärzte in wien

MUW researcher of the month

Researcher of the month